Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01027910 · ClinicalTrials.gov registry record · Phase 1
PCI-24781 in Combination With Doxorubicin to Treat Sarcoma
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT01027910: Completed Phase 1 study, sponsored by Massachusetts General Hospital.
NCT01027910 is a Phase 1 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01027910, a Phase 1 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine the safety and maximum tolerated dose of PCI-24781 that can be given safely with doxorubicin (phase I) and the safety and efficacy of PCI-24781 when used in combination with doxorubicin (phase II) in patients with advanced sarcomas. The study drug, PCI-24781, is believed to regulate genes involved in tumor cell growth. The other study drug, doxorubicin, is considered a standard chemotherapeutic treatment for advanced sarcoma patients. We hypothesize that combining PCI-24781 with doxorubicin can overcome chemoresistance to doxorubicin.
Interventions
- DRUG Doxorubicin
- DRUG GCSF
- DRUG PCI-24781
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2009-02 |
| Est. Completion | 2015-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01027910
The ClinicalTrials.gov registry entry for NCT01027910 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Doxorubicin is the first listed.
NCT01027910 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01027910 about?
NCT01027910 is a clinical study titled "PCI-24781 in Combination With Doxorubicin to Treat Sarcoma". The purpose of this research study is to determine the safety and maximum tolerated dose of PCI-24781 that can be given safely with doxorubicin (phase I) and the safety and efficacy of PCI-24781 when used in combination with doxorubicin (phase II) in patients with advanced sarcomas. The study drug, ...
What is the current status of trial NCT01027910?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2009-02. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01027910?
The interventions under investigation include: Doxorubicin (DRUG), GCSF (DRUG), PCI-24781 (DRUG).
Who is sponsoring clinical trial NCT01027910?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.